First AD

Second AD

Corey Cutler, MD, MPH, discusses the role of prognostic markers in graft-vs-host disease and how they can potentially inform treatment selection.

Role of Biomarkers in Graft-vs-Host Disease

Hematologic Oncology

The OncLive Hematology Oncology condition center page is a comprehensive resource for clinical news and expert insights on various hematologic malignancies, including leukemias, lymphomas, myeloproliferative neoplasms, multiple myeloma, and much more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in hematologic cancers.

Insights

Insights is an expert interview video series of leading oncologists that provides in-depth reports and feature segments profiling leaders in a range of oncology disciplines, including breast cancer, lung cancer, gastrointestinal cancers, genitourinary cancers, gynecologic cancers, and hematologic malignancies. Most episodes feature 2 clinicians discussing the latest oncology advances in clinical practice. 

Advancements and New Treatment Options: Optimizing Care for Patients with Graft-vs-Host Disease

Tulane Cancer Center

Cancer Centers

Partner

Dana-Farber Cancer Institute

Overview of Graft-vs-Host Disease (GvHD)

How Does GvHD Typically Present?

Staging Practices for Chronic Graft-vs-Host Disease

First-Line Therapy for Chronic GvHD

Treating Patients With Steroid-Refractory Chronic GvHD

Approved Therapies for Steroid-Refractory Chronic GvHD

Therapies in Development for Chronic GvHD

Supportive Care and Medication Access in GvHD